[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Lee HS, Cheung DY, Kim JI, Cho SH, Park SH, Han JY, Kim JK: A case of spontaneous regression of advanced gastric cancer. J Korean Med Sci; 2010 Oct;25(10):1518-21
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Esopahgogastroduodenoscopy showed the diffuse infiltrative type of gastric cancer encircling from the cardia to the lower body.
  • On abdominal computerized tomography, the gastric wall was diffusely thickened with overlying mucosal enhancement without lymph node involvement.
  • On esophagogastroduodenoscopy, the gastric mucosa of the body looked normal without any dysplastic change.
  • Abdominal CT revealed a decreased thickening of the gastric wall of the body.
  • The patient is alive without any sign of tumor recurrence after 14 months.
  • [MeSH-major] Adenocarcinoma / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Diabetes Mellitus / drug therapy. Endoscopy, Gastrointestinal. Humans. Hypoglycemic Agents / therapeutic use. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Endocrinol. 2007 Jun;156(6):617-21 [17535860.001]
  • [Cites] Acta Obstet Gynecol Scand. 2008;87(12):1296-300 [18951206.001]
  • [Cites] Urol Int. 2001;66(2):119-20 [11223759.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2000;12(5):335-6 [11315723.001]
  • [Cites] Scand J Urol Nephrol. 2002;36(5):396-8 [12487751.001]
  • [Cites] Immunity. 2004 Aug;21(2):137-48 [15308095.001]
  • [Cites] Abdom Imaging. 2005 Nov-Dec;30(6):734-7 [16252150.001]
  • [Cites] Med J Aust. 1980 Feb 9;1(3):136-7 [6990211.001]
  • [Cites] J Surg Oncol. 1981;17(3):201-9 [6166811.001]
  • [Cites] Dig Dis Sci. 1981 Nov;26(11):1045-50 [6271517.001]
  • [Cites] Acta Oncol. 1990;29(5):545-50 [2206563.001]
  • [Cites] Br J Haematol. 1994 Nov;88(3):621-2 [7819077.001]
  • [Cites] Ann Hematol. 1996 Oct;73(4):189-93 [8890708.001]
  • [Cites] N Engl J Med. 1972 Nov 16;287(20):1013-7 [4650967.001]
  • (PMID = 20890436.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Hypoglycemic Agents
  • [Other-IDs] NLM/ PMC2946665
  • [Keywords] NOTNLM ; Advanced Gastric Cancer / Neoplasm Regression, Spontaneous
  •  go-up   go-down


2. Deans DA, Tan BH, Wigmore SJ, Ross JA, de Beaux AC, Paterson-Brown S, Fearon KC: The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer. Br J Cancer; 2009 Jan 13;100(1):63-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients underwent nutritional assessment consisting of calculation of body mass index, measurement of weight loss, dysphagia scoring and estimation of dietary intake.
  • In all, 182 (83%) patients had lost weight at diagnosis (median loss, 7% body weight).
  • Mechanisms other than reduced dietary intake or mechanical obstruction by the tumour appear to be involved in the nutritional decline in patients with gastro-oesophageal malignancy.
  • Recognition that systemic inflammation plays a role in nutritional depletion may inform the development of appropriate therapeutic strategies to ameliorate weight loss, making patients more tolerant of cancer-modifying treatments such as chemotherapy.
  • [MeSH-major] Esophageal Neoplasms / metabolism. Inflammation / metabolism. Nutritional Status. Stomach Neoplasms / metabolism. Weight Loss
  • [MeSH-minor] Acute-Phase Proteins / analysis. Aged. Deglutition Disorders / metabolism. Eating. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • MedlinePlus Health Information. consumer health - Weight Control.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1974 Feb;33(2):568-73 [4591273.001]
  • [Cites] Br J Cancer. 2004 May 17;90(10):1905-11 [15138470.001]
  • [Cites] Nutr Cancer. 1982;4(1):23-33 [6296795.001]
  • [Cites] N Engl J Med. 1983 Mar 10;308(10):553-8 [6402699.001]
  • [Cites] Lancet. 1985 Apr 6;1(8432):781-4 [2858667.001]
  • [Cites] Br J Cancer. 1987 Dec;56(6):803-8 [3435706.001]
  • [Cites] Cancer Res. 1991 Jan 1;51(1):415-21 [1703040.001]
  • [Cites] J Clin Invest. 1992 May;89(5):1681-4 [1569207.001]
  • [Cites] N Engl J Med. 1993 Oct 28;329(18):1302-7 [7692297.001]
  • [Cites] Immunol Today. 1994 Feb;15(2):74-80 [7512342.001]
  • [Cites] Ann Surg. 1994 Apr;219(4):325-31 [7512810.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2077-82 [7535184.001]
  • [Cites] Am J Physiol. 1995 May;268(5 Pt 1):E813-9 [7762632.001]
  • [Cites] Med Res Rev. 1997 Sep;17(5):477-98 [9276862.001]
  • [Cites] Am J Physiol. 1997 Oct;273(4 Pt 1):E720-6 [9357801.001]
  • [Cites] J Nutr. 1998 Aug;128(8):1355-60 [9687556.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • [Cites] N Engl J Med. 1999 Feb 11;340(6):448-54 [9971870.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1369-79 [10389921.001]
  • [Cites] Clin Exp Immunol. 1999 Sep;117(3):425-9 [10469042.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5802-8 [16115919.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):781-4 [16523196.001]
  • [Cites] Br J Surg. 2007 Dec;94(12):1501-8 [17703501.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Dec;22(12):2288-91 [18031394.001]
  • [Cites] Br J Cancer. 2008 Mar 11;98(5):888-93 [18268490.001]
  • [Cites] Eur J Cancer. 2008 May;44(8):1124-32 [18375115.001]
  • [Cites] Nutr Cancer. 1999;35(2):106-10 [10693162.001]
  • [Cites] Nutr Cancer. 1999;35(2):127-9 [10693165.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2000 Sep;279(3):E707-14 [10950840.001]
  • [Cites] Nutr Hosp. 2001 Jul-Aug;16(4):141-3; discussion 140-1 [11680474.001]
  • [Cites] J Interferon Cytokine Res. 2002 Apr;22(4):473-82 [12034030.001]
  • [Cites] Br J Cancer. 2002 Jul 29;87(3):264-7 [12177792.001]
  • [Cites] Int J Oncol. 2002 Oct;21(4):881-6 [12239630.001]
  • [Cites] Clin Lab Haematol. 2003 Feb;25(1):41-6 [12542441.001]
  • [Cites] Int J Obes Relat Metab Disord. 2003 Feb;27(2):247-52 [12587006.001]
  • [Cites] Gut. 2003 Oct;52(10):1479-86 [12970142.001]
  • [Cites] Am J Med. 1980 Oct;69(4):491-7 [7424938.001]
  • (PMID = 19127266.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Acute-Phase Proteins
  • [Other-IDs] NLM/ PMC2634686
  •  go-up   go-down


3. Thong-Ngam D, Tangkijvanich P, Lerknimitr R, Mahachai V, Theamboonlers A, Poovorawan Y: Diagnostic role of serum interleukin-18 in gastric cancer patients. World J Gastroenterol; 2006 Jul 28;12(28):4473-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lesion location was pyloric-antrum in 39.4%, gastric body in 39.4%, upper stomach in 12.2% and entire stomach in 6.1% of the patients.
  • Surgical treatment was performed in 44.1% patients (total gastrectomy in 5.9%, subtotal gastrectomy in 32.4% and palliative bypass surgery in 5.9%).
  • Systemic chemotherapy was given as an adjuvant therapy in 8.8% patients.
  • The mean survival time was 13.03 +/- 9.75 mo.
  • The cut point of IL-18 for diagnosis of gastric cancer was 40 pg/mL, the positive predictive value was 92.31%.
  • [MeSH-major] Biomarkers, Tumor / blood. Interleukin-18 / blood. Stomach Neoplasms / blood. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Enzyme-Linked Immunosorbent Assay. Female. Humans. Interleukin-10 / blood. Interleukin-10 / physiology. Interleukin-12 / blood. Interleukin-12 / physiology. Interleukin-6 / blood. Interleukin-6 / physiology. Male. Middle Aged. Neoplasm Metastasis / physiopathology. Predictive Value of Tests. Prognosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastric Cancer. 2005;8(2):124-31 [15864720.001]
  • [Cites] Gastric Cancer. 2005;8(2):86-94 [15864715.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2661-9 [10914707.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4838-44 [10987295.001]
  • [Cites] Annu Rev Immunol. 2001;19:423-74 [11244043.001]
  • [Cites] J Med Assoc Thai. 2001 Apr;84(4):475-82 [11460956.001]
  • [Cites] J Clin Gastroenterol. 2002 Apr;34(4):416-20 [11907352.001]
  • [Cites] J Surg Res. 2004 Feb;116(2):277-87 [15013367.001]
  • [Cites] Ann Surg. 1987 Jan;205(1):1-8 [3800453.001]
  • [Cites] Cytokine. 1991 May;3(3):212-23 [1653054.001]
  • [Cites] Int J Cancer. 1991 Oct 21;49(4):513-9 [1917151.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1731-5 [8448737.001]
  • [Cites] Adv Immunol. 1993;54:1-78 [8379461.001]
  • [Cites] Ann Surg. 1993 Nov;218(5):583-92 [8239772.001]
  • [Cites] Int J Cancer. 1993 Dec 2;55(6):891-903 [8253525.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Jul-Aug;3(5):445-51 [7920213.001]
  • [Cites] Dig Dis. 1994 Sep-Oct;12(5):276-89 [7882548.001]
  • [Cites] Nature. 1995 Nov 2;378(6552):88-91 [7477296.001]
  • [Cites] Semin Oncol. 1996 Jun;23(3):281-91 [8658212.001]
  • [Cites] Eur J Cancer Prev. 1996 Oct;5(5):405-8 [8972278.001]
  • [Cites] J R Soc Med. 1996 Dec;89(12):674-8 [9014876.001]
  • [Cites] Gut. 1997 Jun;40(6):739-44 [9245927.001]
  • [Cites] Jpn J Cancer Res. 1997 Oct;88(10):953-8 [9414656.001]
  • [Cites] J Clin Invest. 1998 Mar 15;101(6):1441-52 [9502787.001]
  • [Cites] Annu Rev Immunol. 1998;16:495-521 [9597139.001]
  • [Cites] Br Med Bull. 1998;54(1):139-50 [9604438.001]
  • [Cites] J Leukoc Biol. 1998 Jun;63(6):658-64 [9620656.001]
  • [Cites] J Biol Regul Homeost Agents. 1998 Jan-Jun;12(1-2):38-41 [9677534.001]
  • [Cites] J Clin Immunol. 1999 Jan;19(1):1-11 [10080100.001]
  • [Cites] Eur Cytokine Netw. 2000 Mar;11(1):15-26 [10705295.001]
  • (PMID = 16874857.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-18; 0 / Interleukin-6; 130068-27-8 / Interleukin-10; 187348-17-0 / Interleukin-12
  • [Other-IDs] NLM/ PMC4125632
  •  go-up   go-down


Advertisement
4. Shinchi H, Maemura K, Noma H, Mataki Y, Kurahara H, Maeda S, Kitazono M, Nakashima H, Maenohara S, Natsugoe S, Takao S: [A case of effective treatment with chemosensitivity test-guided chemotherapy for advanced pancreatic and gastric cancer with peritoneal metastasis]. Gan To Kagaku Ryoho; 2008 Jun;35(6):1009-12
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of effective treatment with chemosensitivity test-guided chemotherapy for advanced pancreatic and gastric cancer with peritoneal metastasis].
  • A 63-year-old man with abdominal pain was diagnosed as locally advanced pancreatic tail cancer and gastric cancer with peritoneal metastasis based on computed tomography (CT) and gastrointestinal series.
  • An ileoileostomy was performed and peritoneal tissue was submitted to a chemosensitivity test.
  • Based on the chemosensitivity test, CPT-11 (50 mg/body), 5-FU (750 mg/body), and Leucovorin (375 mg/body) were administered intravenously once a week for 3 weeks with a 1-week rest as 1 course.
  • The patient received 9 courses of chemotherapy until progressive disease.
  • Stable disease in tumor size was observed and serum CA19-9 level dropped to 81 U/mL.
  • He died of peritoneal dissemination 26 months after diagnosis.
  • Chemosensitivity test-guided chemotherapy seems to be an effective regimen as individualized chemotherapy for advanced pancreatic and gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed. Treatment Failure

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633235.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Kojima Y, Kii T, Takiuchi H, Kuwakado S, Kawabe S, Gotoh M, Yoshida M, Higuchi K, Egashira Y, Tanigawa N: [A resected case of effective treatment with S-1+CPT-11 combination chemotherapy for advanced gastric cancer]. Gan To Kagaku Ryoho; 2010 Jul;37(7):1381-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A resected case of effective treatment with S-1+CPT-11 combination chemotherapy for advanced gastric cancer].
  • We report a resected case of effective treatment with S-1+CPT-11 combination chemotherapy for advanced gastric cancer.
  • The patient was a 65-year-old man who had a type 3 gastric cancer from the middle body of the stomach to the angle.
  • An abdominal CT scan demonstrated bulky lymph node metastasis (cType 3, T3, N2, M0, cStage IIIb), which was then treated with S-1+CPT-11 (S-1 80 mg/m2 day 1-21, CPT-11 80 mg/m2 day 1, 15/5 weeksx2 courses)as neoadjuvant chemotherapy.
  • After 2 courses of chemotherapy, the primary lesion and regional metastatic lymph nodes were reduced by CT (cType 3, T2, N2, M0, cStage IIIa).
  • The histological diagnosis was pT2 (ss), pN0, sH0, pCY0, sP0, sM0, tub2, INF beta, ly0, v1, n0, stage I b, Cur A, and the histological effect of the main tumor was judged to be Grade 1b.
  • This case suggests that neoadjuvant chemotherapy with S-1+CPT-11 is a potential regimen for advanced gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Neoadjuvant Therapy. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Combinations. Gastrectomy. Gastroscopy. Humans. Male. Neoplasm Staging. Remission Induction. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647732.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


6. Koizumi S, Iwasaki Y, Ohashi M, Iwanaga T, Ohinata R, Takahashi K, Yamaguchi T, Matsumoto H, Nakano D, Tateishi Y: [A successfully treated case of type 4 gastric cancer with intraperitoneal free cancer cells undergoing a curative resection followed by neoadjuvant chemotherapy with S-1 plus cisplatin]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2464-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A successfully treated case of type 4 gastric cancer with intraperitoneal free cancer cells undergoing a curative resection followed by neoadjuvant chemotherapy with S-1 plus cisplatin].
  • Gastrofiberscopy revealed that type 4 gastric cancer located at the whole gastric body.
  • Although abdominal computed tomography showed that no distant metastasis but regional lymph node metastasis existed, staging laparoscopy and cytological diagnosis revealed that there were intraperitoneal free cancer cells without overt peritoneal metastasis(P0CY1).
  • She received neoadjuvant chemotherapy with S-1 plus cisplatin for consecutive 21 days followed by 7 days of rest as a course.
  • After 3 courses of the chemotherapy, intraperitoneal free cancer cells were not found, and she underwent curative gastrectomy.
  • Pathological examination showed that the therapeutic effect was Grade 2.
  • S-1 as postoperative chemotherapy had been prescribed for 10 months without relapse.
  • She has received a weekly paclitaxel therapy as second-line chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Neoadjuvant Therapy / methods. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Combinations. Female. Humans. Neoplasm Staging. Neoplastic Cells, Circulating / pathology. Oxonic Acid / administration & dosage. Peritoneal Cavity. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224607.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Koide N, Suzuki A, Saito H, Sato T, Murakami M, Ota H, Miyagawa S: Gastric small cell carcinoma successfully treated by surgery and postoperative chemotherapy consisting of cisplatin and S-1: report of a case. Surg Today; 2007;37(11):989-94
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric small cell carcinoma successfully treated by surgery and postoperative chemotherapy consisting of cisplatin and S-1: report of a case.
  • We herein report a case of gastric small cell carcinoma (GSCC), which was successfully treated by surgery and postoperative chemotherapy consisting of cisplatin (CDDP) and the fluoropyrimidine S-1.
  • The patient was a 63-year-old man in whom a gastric tumor had been endoscopically detected.
  • The type 1 tumor was located in the gastric body.
  • An abdominal computed tomogram showed many metastasized nodes around the stomach.
  • The removed tumor was histologically and histochemically diagnosed to be a GSCC with node metastases.
  • We reviewed 52 Japanese patients with GSCC/endocrine cell carcinoma (EC) reported between 2001 and 2005 with reference to chemotherapy.
  • Chemotherapy using S-1 was performed for 11 of the 52 patients.
  • Four of the 11 patients, including the present case, who were treated with S-1 survived for over 2 years after surgery, although the GSCC/EC of the four patients were staged as III or IV.
  • Therefore, chemotherapy consisting of CDDP and S-1 may provide a survival benefit for patients with GSCC/EC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Small Cell / drug therapy. Cisplatin / therapeutic use. Gastrectomy / methods. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Diagnosis, Differential. Drug Combinations. Drug Therapy, Combination. Endoscopy, Gastrointestinal. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Period. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1567-70 [15362803.001]
  • [Cites] Dig Dis Sci. 1990 Apr;35(4):513-8 [2156662.001]
  • [Cites] Gastric Cancer. 2004;7(2):122-7 [15224200.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Jun;18(6):743-7 [12753162.001]
  • [Cites] Fukuoka Igaku Zasshi. 1976 Feb;67(2):65-73 [177344.001]
  • [Cites] Am J Clin Oncol. 1998 Oct;21(5):458-61 [9781599.001]
  • [Cites] Am J Gastroenterol. 1991 Sep;86(9):1167-75 [1715667.001]
  • [Cites] Gastric Cancer. 2005;8(2):111-6 [15864718.001]
  • [Cites] Anticancer Drugs. 1996 Jul;7(5):548-57 [8862723.001]
  • [Cites] Oncology. 1999 Oct;57(3):202-10 [10545788.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Surg Today. 1999;29(2):165-9 [10030743.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):85-91 [11784874.001]
  • [Cites] Cancer. 1990 Feb 1;65(3):422-4 [1688727.001]
  • [Cites] Arch Pathol Lab Med. 1998 Nov;122(11):1010-7 [9822131.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12):2207-12 [14676796.001]
  • [Cites] Surg Today. 2003;33(4):294-8 [12707827.001]
  • (PMID = 17952533.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Oshima N, Tanizawa Y, Bando E, Kawamura T, Tokunaga M, Sugisawa N, Taki Y, Motegi Y, Boku N, Sasaki K, Terashima M: [Histological complete response in a case of advanced gastric cancer treated by neo-adjuvant chemotherapy with S-1/CDDP]. Gan To Kagaku Ryoho; 2010 Apr;37(4):697-701
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histological complete response in a case of advanced gastric cancer treated by neo-adjuvant chemotherapy with S-1/CDDP].
  • Since curative surgery was deemed not feasible, we tried neoadjuvant chemotherapy expecting downstaging of the tumor.
  • S-1(120 mg/body)was orally administered for three weeks followed by one week rest, and CDDP(60 mg/m2)was administered on day 8.
  • Three courses of treatment resulted in a marked shrinkage of the primary lesion and a reduction of lymph nodes.
  • The histological diagnosis revealed complete disappearance of cancer cells in the primary lesion of the stomach and lymph nodes, confirming a pathological complete response.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Neoadjuvant Therapy. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Drug Combinations. Humans. Male. Middle Aged. Neoplasm Staging. Remission Induction. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414029.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Mizutani S, Oyama T, Uchikoshi F, Yoshidome K, Tori M, Ueshima S, Hiraoka K, Yamagami Y, Takahashi H, Nakahara M: [A case of advanced gastric cancer with peritoneal dissemination responding to S-1/CDDP neoadjuvant chemotherapy]. Gan To Kagaku Ryoho; 2007 Nov;34(11):1853-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with peritoneal dissemination responding to S-1/CDDP neoadjuvant chemotherapy].
  • The patient was a 72-year-old male diagnosed with type III poorly-differentiated adenocarcinoma in the lesser curvature by gastric fiberscopy.
  • An abdominal computed tomography (CT) scan showed the thickness of the gastric wall and the enlarged lymph node around the stomach and laparoscopic examination revealed peritoneal dissemination.
  • The patient received neoadjuvant combined chemotherapy with S-1 and CDDP.
  • S-1 (100 mg/day) was orally administered for 3 weeks followed by 2 drug-free weeks as a course, and CDDP (100 mg/body) was administered by intravenous drip on day 8.
  • After the third course, significant tumor reduction was obtained.
  • Peritoneal dissemination disappeared, and the histological diagnosis revealed complete disappearance of cancer cells in the ascites and no metastasis in all lymph nodes.
  • The combined neoadjuvant chemotherapy with S-1 and CDDP can be an effective treatment of choice for advanced gastric carcinoma with peritoneal dissemination.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Peritoneal Neoplasms / secondary. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Humans. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Oxonic Acid / administration & dosage. Remission Induction. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030023.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Matono S, Horiuchi H, Kishimoto Y, Sasahara H, Ureshino M, Kashihara M, Sueyoshi S, Shirouzu K: [A case of advanced gastric cancer with giant lymph node metastasis responding to S-1/CDDP neoadjuvant chemotherapy]. Gan To Kagaku Ryoho; 2008 Sep;35(9):1573-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with giant lymph node metastasis responding to S-1/CDDP neoadjuvant chemotherapy].
  • Since a radical resection appeared impossible, we tried neoadjuvant chemotherapy (NAC) with S-1/CDDP, expecting down staging of the tumor.
  • S-1 (120 mg/body) was orally administered for 21 days and CDDP (40 mg/body) was administered by intravenous drip on day 8, 15 and 22.
  • Partial response (PR) was obtained after 2 courses, and distal gastrectomy with D2 lymph node dissection was performed.
  • The histological diagnosis revealed complete disappearance of cancer cells in stomach and a few regional lymph node metastasis (3/30).
  • We considered the S-1 and CDDP in combination useful as preoperative chemotherapy for advanced gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Neoadjuvant Therapy. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Drug Combinations. Gastroscopy. Humans. Lymphatic Metastasis / pathology. Male. Neoplasm Staging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18799914.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Aoyama T, Saeki H, Samejima J, Fujii K, Ishikawa Y, Kawamoto M, Fujisawa J, Matsukawa H, Rino Y, Masuda M: [A case of recurrent gastrointestinal stromal tumor of the stomach with complete response to imatinib mesilate]. Gan To Kagaku Ryoho; 2009 Jun;36(6):975-8
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent gastrointestinal stromal tumor of the stomach with complete response to imatinib mesilate].
  • We report a patient who long had a complete response by chemotherapy with imatinib mesilate(IM)for locally recurrent gastrointestinal stromal tumor(GIST)of the stomach.
  • Endoscopic examination revealed continuous bleeding from a submucosal tumor with ulceration on the posterior wall of the stomach.
  • The diagnosis made was GIST from immunohistological findings of positive c-kit, positive CD34, negative HMB45, and negative S100.
  • After diagnosis, total gastrectomy, distal pancreatectomy, and splenectomy were performed.
  • On September 2003, a local recurrence was recognized, and then chemotherapy by 400 mg IM daily was started.
  • After beginning with a dose of IM 400 mg daily, the reduction of the tumor was monitored.
  • Because of the adverse side effects of IM, systemic edema and body weight increased.
  • After reduction of IM, the adverse reactions resolved promptly, and a complete response of the primary tumor has been maintained for 4 years 3 months.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Benzamides. Female. Humans. Imatinib Mesylate. Middle Aged. Neoplasm Recurrence, Local. Remission Induction

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542718.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


12. Sugishita H, Ishida N, Yoshida M, Sato K, Doi T, Horiuchi A, Watanabe Y: [A case of cervical lymph node recurrence of advanced gastric cancer responding to combination therapy of S-1, CDDP and docetaxel]. Gan To Kagaku Ryoho; 2010 Jul;37(7):1385-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of cervical lymph node recurrence of advanced gastric cancer responding to combination therapy of S-1, CDDP and docetaxel].
  • The post operative diagnosis was Stage IIIB (tubular adenocarcinoma, moderately-differentiated type, SE, N2, M0).
  • The patient's postoperative course was uneventful, and S-1 was administered as adjuvant chemotherapy.
  • However, about 14 months later, a gradual left cervical lymph node swelling became evident, with an increase in the level of the tumor marker CA19-9, suggesting recurrence of the gastric cancer.
  • After obtaining informed consent, S-1 (100 mg/body), cisplatin (60 mg/m2), and docetaxel (40 mg/m2) combination chemotherapy (DCS) was performed.
  • At three months since the last chemotherapy, the patient showed no signs of recurrence.
  • DCS is a potentially effective treatment for recurrent gastric cancer with resistance to S-1.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Neck / pathology. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Taxoids / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Drug Combinations. Humans. Lymphatic Metastasis / radiography. Lymphatic Metastasis / radionuclide imaging. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Recurrence. Remission Induction. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647733.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Iijimal S, Makari Y, Handa R, Kato T, Ooshima S, Miyake Y, Hoshi M, Doi T, Kurokawa E, Kikkawa N: [A 14-month surviving patient on advanced esophageal cancer with big lymph node metastasis to cardia responding to S-1 plus cisplatin (CDDP) therapy at home]. Gan To Kagaku Ryoho; 2008 Dec;35 Suppl 1:7-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A 14-month surviving patient on advanced esophageal cancer with big lymph node metastasis to cardia responding to S-1 plus cisplatin (CDDP) therapy at home].
  • He was hospitalized with some dysphasia and a severe body weight loss since August 2004.
  • The diagnosis was the esophageal cancer (type 2, 11 cm) with big lymph node metastasis on cardia (8 cm), and also pathologically poorly differentiated squamous cell carcinoma from two legions.
  • He wanted a home chemotherapy for it.
  • We administered a combination chemotherapy of S-1 plus cisplatin (CDDP) therapy.
  • An eight-day admission within an each course to CDDP treatment and nutritional support were required for adverse events of anorexia (grade 3), but for other days home chemotherapy was done with good compliance of S-1 up to 6 courses.
  • After 6 courses of S-1 + plus cisplatin in May 2005, a home S-1 single therapy which was not needed the admission started at will.
  • But the lymph node mass of cardia progressed again in September 2005, and his therapy moved to the terminal care at home.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cardia / pathology. Cisplatin / therapeutic use. Esophageal Neoplasms / drug therapy. Home Care Services. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Combinations. Esophagoscopy. Fatal Outcome. Gastroscopy. Humans. Lymphatic Metastasis. Male. Neoplasm Staging. Terminal Care. Time Factors. Tomography, X-Ray Computed


14. Ahmad A, Govil Y, Frank BB: Gastric mucosa-associated lymphoid tissue lymphoma. Am J Gastroenterol; 2003 May;98(5):975-86
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric mucosa-associated lymphoid tissue lymphoma.
  • The connection between Helicobacter pylori and gastric mucosa-associated lymphoid tissue (MALT) lymphoma is well established. H. pylori infection causes an immunological response, leading to chronic gastritis with formation of lymphoid follicles within the stomach.
  • These lymphoid follicles resemble nodal tissues found throughout the body and are composed of reactive T cells and activated plasmal cells and B cells.
  • Early diagnosis of MALT lymphoma is difficult but essential for adequate treatment.
  • The endoscopic appearance of this tumor is varied and can be infiltrative, exophytic, or ulcerative.
  • In addition, the tumor can have a multifocal distribution, and therefore aggressive tissue sampling is crucial for diagnosis.
  • Endoscopic ultrasound is essential to document the extent of disease and is more accurate than CT scan in detection of spread to perigastric lymph nodes.
  • Those MALT lymphomas that present at more advanced stages require more aggressive management and can be treated with surgical resection, radiation, or chemotherapy.
  • Follow-up is critical in all patients who have been treated with H. pylori eradication and consists of multiple endoscopic biopsies for histological and molecular studies as well as endoscopic ultrasound at 3, 6, and 12 months after treatment.
  • The reappearance of MALT lymphomas has been seen years after treatment, and therefore follow-up of these patients should be indefinite.
  • [MeSH-major] Helicobacter Infections / complications. Lymphoma, B-Cell, Marginal Zone. Stomach Neoplasms
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Anti-Ulcer Agents / therapeutic use. Clinical Trials as Topic. Gastric Mucosa / microbiology. Gastric Mucosa / pathology. Gastroscopy. Helicobacter pylori / immunology. Helicobacter pylori / isolation & purification. Humans. Molecular Biology. Neoplasm Staging / methods

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12809817.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Ulcer Agents
  • [Number-of-references] 99
  •  go-up   go-down


15. Flamen P: Positron emission tomography in gastric and esophageal cancer. Curr Opin Oncol; 2004 Jul;16(4):359-63
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography in gastric and esophageal cancer.
  • PURPOSE OF REVIEW: Positron emission tomography using the positron emitting glucose analogue 18F-fluorodeoxyglucose has recently emerged as a promising metabolism-based whole-body imaging tool for cancer diagnosis and follow-up.
  • The review limits its scope to the recent advances of 18F-fluorodeoxyglucose positron emission tomography in the clinical management of gastric and esophageal cancer.
  • RECENT FINDINGS: New studies have been reported on the use of 18F-fluorodeoxyglucose positron emission tomography to assess the early and late metabolic response of a gastroesophageal tumor to chemo(radiation) therapy.
  • The metabolic response as measured by serial 18F-fluorodeoxyglucose positron emission tomography, performed before and during treatment or some weeks thereafter, can be used to predict the clinical and histopathologic response.
  • Moreover, the metabolic positron emission tomography response seems to be related to overall and disease-free survival.
  • SUMMARY: Gastroesophageal 18F-fluorodeoxyglucose positron emission tomography could add significant diagnostic information to the different phases of patient management.
  • At initial diagnosis of esophageal cancer, positron emission tomography detects more distant lymph node and organ metastases compared with conventional diagnostics, allowing a more accurate selection of the most appropriate treatment.
  • Serial 18F-fluorodeoxyglucose positron emission tomography performed before and during chemotherapy allows early identification of nonresponding tumors.
  • 18F-fluorodeoxyglucose positron emission tomography performed after a treatment allows accurate assessment of the residual tumor load.
  • 18F-fluorodeoxyglucose positron emission tomography allows accurate detection and restaging of recurrent disease.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Esophageal Neoplasms / radionuclide imaging. Stomach Neoplasms / radionuclide imaging. Tomography, Emission-Computed
  • [MeSH-minor] Fluorodeoxyglucose F18. Humans. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radionuclide imaging. Neoplasm Recurrence, Local / therapy. Neoplasm Staging. Remission Induction

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15187891.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 22
  •  go-up   go-down


16. Lim ST, Jeong HJ, Kim DW, Yim CY, Sohn MH: F-18 FDG PET-CT findings of intraperitoneal carbon particles-induced granulomas mimicking peritoneal carcinomatosis. Clin Nucl Med; 2008 May;33(5):321-4
Hazardous Substances Data Bank. CARBON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All 3 patients had a history of intraperitoneal chemotherapy using mitomycin C bound to activated carbon particles during surgery.
  • [MeSH-major] Carbon / adverse effects. Fluorodeoxyglucose F18. Granuloma, Foreign-Body / chemically induced. Granuloma, Foreign-Body / diagnosis. Mitomycin / adverse effects. Peritoneal Neoplasms / diagnosis. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Diagnosis, Differential. Extravasation of Diagnostic and Therapeutic Materials / diagnosis. Extravasation of Diagnostic and Therapeutic Materials / etiology. False Positive Reactions. Female. Humans. Male. Middle Aged. Neoplasm, Residual / diagnosis. Particle Size. Radiopharmaceuticals. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18431143.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 50SG953SK6 / Mitomycin; 7440-44-0 / Carbon
  •  go-up   go-down


17. Dinakar P, Höke A: Paraneoplastic fasciitis-panniculitis syndrome: a neurological point of view. Nat Clin Pract Neurol; 2009 Feb;5(2):113-7
Genetic Alliance. consumer health - Panniculitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Her symptoms improved remarkably on initiation of chemotherapy and worsened on discontinuation of chemotherapy.
  • INVESTIGATIONS: Neurological examination, MRI of the abdomen and lower extremities, whole-body fluorodeoxyglucose PET, pan-CT scan, electromyography, muscle biopsy, upper gastrointestinal tract radiography, esophagogastroduodenoscopy, and immunophenotyping (paraneoplastic, rheumatological and autoimmune diseases panels).
  • DIAGNOSIS: Paraneoplastic fasciitis-panniculitis syndrome associated with the recurrence of poorly differentiated signet ring gastric adenocarcinoma.
  • MANAGEMENT: Chemotherapy of recurrent gastric adenocarcinoma and symptomatic management of painful spasms.
  • [MeSH-major] Neoplasm Recurrence, Local. Panniculitis. Paraneoplastic Syndromes
  • [MeSH-minor] Female. Gastrectomy / methods. Humans. Magnetic Resonance Imaging / methods. Middle Aged. Positron-Emission Tomography. Stomach Neoplasms / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194391.001).
  • [ISSN] 1745-8358
  • [Journal-full-title] Nature clinical practice. Neurology
  • [ISO-abbreviation] Nat Clin Pract Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Li J, Liu P, Wang H, Yu J, Xie P, Liu X: [Clinical analysis of 31 patients with gastric stromal tumors]. Zhonghua Nei Ke Za Zhi; 2002 Nov;41(11):742-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinical manifestations, diagnosis and treatment of gastric stromal tumors.
  • The distribution of gastric tromal tumors is fundus > body > antrum.
  • Diagnosis of this condition is sometimes difficult and treatment is often delayed because patients usually present with nonspecific abdominal symptoms.
  • Gastroscopy, ultrasound gastroscopy, computed tomography, B type ultrasound and upper gastrointestinal X-ray series are helpful to diagnosis.
  • But the final diagnosis is decided by pathological and immunohistochemistry examinations.
  • The operative treatment is thought of the first choice.
  • Effect of the chemotherapy isn't satisfied.
  • There is no standard chemotherapy for gastric stromal tumors.
  • CONCLUSIONS: Gastric stromal tumor is a kind of separated submucosal tumor which is different from leiomyoma, leiomyosarcoma and neurogenic tumors.
  • Pathological and immunohistochemistry inspectations are very important to make clear diagnosis.
  • Early diagnosis and rational treatment are the keys to improve the prognosis.
  • [MeSH-major] Stomach Neoplasms / physiopathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12485519.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


19. Matsui K, Nashimoto A, Nakagawa S, Nomura T, Yabusaki H, Takii Y, Tsuchiya Y, Tanaka O, Ohta T: [A case of advanced gastric cancer responding to neoadjuvant S-1/CDDP therapy]. Gan To Kagaku Ryoho; 2008 Mar;35(3):499-501
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer responding to neoadjuvant S-1/CDDP therapy].
  • Gastrointestinal endoscopic examination revealed type 2 advanced gastric cancer.
  • Computed tomography revealed metastatic Bulkey group 2 lymph nodes.
  • The diagnosis was sStage IIIB gastric cancer (sT3 sN2sH0 sP0 CY0) at staging laparoscopy.
  • S-1 (100 mg/body/day) was orally administered for 3 weeks followed by a drug-free 2 weeks, and CDDP (74 mg/body/day) was given intravenously on day 8.
  • After 3 courses of chemotherapy, the primary lesion and the regional lymph nodes were significantly reduced in size.
  • The final diagnosis was T2N0 H0 P0, fStageIB and curability A.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Neoadjuvant Therapy. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Combinations. Humans. Male. Neoplasm Staging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347404.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Sakusabe M, Ouchi S, Seki H, Kumagai Y, Kamata S, Kotanagi H: [A case of effective weekly paclitaxel administration for gastric cancer recurrence with carcinomatous pericarditis]. Gan To Kagaku Ryoho; 2005 Jan;32(1):77-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 69-year-old man underwent distal gastrectomy for gastric cancer in December 2001.
  • A diagnosis of cardiac tamponade caused by gastric cancer relapse was made, and the patient was treated by weekly paclitaxel administration (90 mg/body) after drainage.
  • It was effective in preventing reaccumulation of the pericardial effusion until his death 73 days after the diagnosis.
  • It is thought that weekly paclitaxel administration can be a treatment for carcinomatous pericarditis.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Neoplasm Recurrence, Local / complications. Paclitaxel / therapeutic use. Pericarditis / drug therapy. Stomach Neoplasms / complications
  • [MeSH-minor] Aged. Drainage. Drug Administration Schedule. Gastrectomy. Humans. Male. Pericardial Effusion / prevention & control

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15675587.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


21. Akazawa N, Taguchi K, Imai A, Kikuchi H, Minato M, Iwaki H: [A case of advanced gastric cancer responding to S-1/paclitaxel/lentinan as neoadjuvant chemoimmunotherapy]. Gan To Kagaku Ryoho; 2010 Jul;37(7):1365-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We thought a complete resection would be difficult, so he was treated with neo-adjuvant immunochemotherapy in combination with S-1 80 mg/m2 (2 weeks administration and 2-week rest), paclitaxel (PTX) 50 mg/m2 (day 1, 8, 15) and Lentinan (LNT) 2 mg/body (day 1, 8, 15).
  • After 5 courses of this treatment, swollen lymph nodes decreased in size and the metastatic liver tumor disappeared.
  • The histological diagnosis was pT2 pN0, Stage I B.
  • Histological effects of primary tumor and lymphnodes were judged to be grade 2 and grade 3, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lentinan / therapeutic use. Neoadjuvant Therapy. Oxonic Acid / therapeutic use. Paclitaxel / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Combinations. Gastrectomy. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Lymph Node Excision. Lymphatic Metastasis / radiography. Male. Neoplasm Staging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647728.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 37339-90-5 / Lentinan; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


22. Waguri N, Furukawa K, Shobugawa K, Takizawa K, Ikeda H, Iwamoto Y, Aiba T, Yoneyama O, Igarashi K, Tsukioka S, Yabe M, Kuwabara S, Shibuya H: [A case of gastric cancer with abdominal wall invasion treated by weekly low-dose paclitaxel therapy]. Gan To Kagaku Ryoho; 2006 Aug;33(8):1151-4
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of gastric cancer with abdominal wall invasion treated by weekly low-dose paclitaxel therapy].
  • Here we report a case of gastric cancer with diffuse abdominal wall invasion treated with weekly low-dose paclitaxel therapy.
  • A 62-year-old male visited our hospital because of abdominal distention, prepubic tumor,and testicular hydrocele.
  • Computed tomography revealed diffuse swelling of the abdominal wall and hydronephrosis of the right kidney.
  • Upper gastrointestinal endoscopy demonstrated type 3' advanced gastric cancer.
  • Pathological diagnosis of both gastric tumor and abdominal wall biopsy specimens was poorly-differentiated adenocarcinoma containing signet ring cell carcinoma.
  • Low-dose paclitaxel (90 mg/body) was given once a week for 3 weeks.
  • Abdominal wall swelling like cuirass disappeared after 2 courses of low-dose paclitaxel therapy.
  • [MeSH-major] Abdominal Wall / pathology. Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Paclitaxel / administration & dosage. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Carcinoma, Signet Ring Cell / pathology. Drug Administration Schedule. Humans. Male. Middle Aged. Neoplasm Invasiveness. Radiography, Abdominal. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912538.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


23. Imai H, Obana N, Iwabuchi T, Satou Y, Ooyauchi M, Igarashi T, Matsumoto H, Sakamoto K: [Long survival of advanced gastric cancer patient after total gastrectomy and postoperative treatment with S-1 despite S-1+CDDP+CPT-11 causing perforation]. Gan To Kagaku Ryoho; 2008 Jul;35(7):1185-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long survival of advanced gastric cancer patient after total gastrectomy and postoperative treatment with S-1 despite S-1+CDDP+CPT-11 causing perforation].
  • Here we report a rare case with perforation of gastric cancer responding to chemotherapy.
  • The patient was a 74- year-old male who underwent abdominal ultrasonography and contrast CT because of body-weight lost and poor appetite in June, 2004 and whose lymph node(LN)swelling was seen in the level from the hepatic to the renal hilum.
  • Then it demonstrated type 2 advanced gastric cancer from the upper to the middle body.
  • The pathological diagnosis of gastric tumor was poorly-differentiated adenocarcinoma containing por 2, tub 1, and pap.
  • The patient was treated with S-1, CDDP and CPT-11 and remained ambulant.
  • After completion of 1 course of chemotherapy, he complained of intense abdominal pain, so we carried out upper gastrointestinal endoscopy and found perforation in the stomach at the same location as the gastric cancer.
  • The histopathological finding showed disappearance of the cancer cell not only in the stomach but also accessory LN.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Cisplatin / therapeutic use. Gastrectomy. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Combinations. Gastroscopy. Humans. Male. Neoplasm Staging. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633259.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


24. Kobayashi K, Yokote T, Akioka T, Hara S, Oka S, Hirata Y, Miyoshi T, Tsuji M, Hanafusa T: [Primary gastric T-cell lymphoma with predominant bone marrow infiltration undergoing aggressive clinical course]. Gan To Kagaku Ryoho; 2007 Apr;34(4):647-51
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Upper gastroduodenal endoscopy revealed a gastric tumor in the greater curvature of the body.
  • The diagnosis was HTLV-1 unassociated primary gastric T-cell lymphoma with bone marrow infiltration.
  • After undergoing oral chemotherapy with VP-16 at 25 mg/day, combination chemotherapy was initiated with vincristine 2 mg/day and dexamethasone 48 mg/day.
  • The man died with the aggressive clinical course after combination chemotherapy.
  • [MeSH-major] Bone Neoplasms / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Lymphoma, T-Cell / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Antigens, CD20 / analysis. Antigens, CD3 / analysis. Humans. Immunophenotyping. Male. Middle Aged. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431359.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3
  •  go-up   go-down


25. Luo ZG, Feng FY, Zhang P, Wang XY, Wang QL: [Clinical analysis of 68 patients with primary gastric lymphoma]. Ai Zheng; 2004 Dec;23(12):1692-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVES: Stomach is the most common extranodal involvement site of lymphoma.
  • Treatment patterns for primary gastric lymphoma (PGL) are controversial now.
  • This study was to investigate clinical features, treatment patterns, and prognostic factors of patients with PGL.
  • Thirty-seven patients received surgery plus chemotherapy,7 received surgery plus chemoradiotherapy,9 received surgery plus radiotherapy,9 received surgery plus chemotherapy, 4 received surgery alone,and 2 were untreated.
  • Common lesions of PGL were in gastric body, and gastric antrum.
  • Diagnosis rate of gastroscopy biopsy was 53.2%, that of X-ray barium meal was 40.9%.
  • CONCLUSIONS: Treatment of PGL should be based on combined therapy of surgery, chemotherapy, and radiotherapy.
  • [MeSH-major] Gastrectomy. Lymphoma, Non-Hodgkin / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prognosis. Proportional Hazards Models. Radiotherapy, High-Energy. Retrospective Studies. Survival Rate. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15601562.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


26. Funk L, Hartmann D, Apel D, Spiethoff A, Schiele R, Schilling D, Adamek HE, Riemann JF: [Symptomatic pericardial effusion as initial manifestation of gastric signet ring cell carcinoma]. Dtsch Med Wochenschr; 2003 Apr 17;128(16):870-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The health history included the diagnosis of diabetes mellitus and chronic obstructive pulmonary disease.
  • The cytology showed signet ring cells from the stomach.
  • Endoscopic study revealed a 3 cm tumor in the posterior wall of the upper part of the body.
  • The histopathological examination diagnosed cancer of diffuse type according to Lauren, with signet-ring cells.
  • TREATMENT AND CLINICAL COURSE: After treating the atrial fibrillation a pericardial drainage was performed.
  • During the clinical course the patient suffered a stroke and the chemotherapy could not be initiated.
  • The patient died 2 months after diagnosis.
  • CONCLUSION: Cardiac involvement with clinical manifestations and pericardial effusion may be associated with a malignant neoplasm.
  • Echocardiography and pericardiocentesis are helpful for the diagnosis of cardiac metastases.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Pericardial Effusion / etiology. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Aged. Atrial Fibrillation / diagnosis. Atrial Fibrillation / etiology. Atrial Fibrillation / therapy. Drainage. Dyspnea. Fatal Outcome. Female. Gastroscopy. Humans. Pericardiocentesis. Tachycardia

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12701032.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement